Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Circulation ; 104(25): 3145-51, 2001 Dec 18.
Article in English | MEDLINE | ID: mdl-11748115

ABSTRACT

BACKGROUND: Interleukin (IL)-12 exerts a potent proinflammatory effect by stimulating T-helper (Th) 1 responses. This effect is believed to be mediated primarily through the activation of STAT4 and subsequent production of interferon (IFN)-gamma. Methods and Results- We examined the role of IL-12 receptor (IL-12R) signaling in the development of murine experimental autoimmune myocarditis (EAM) induced by cardiac myosin immunization. Both IL-12Rbeta1-deficient mice and STAT4-deficient mice were resistant to the induction of myocarditis. Treatment with exogenous IL-12 exacerbated disease. We questioned whether IFN-gamma is required for the disease-promoting activity of IL-12. On the contrary, we found that IFN-gamma suppresses EAM. Lack of IFN-gamma due to either depletion with an antibody or a genetic deficiency exacerbated myocarditis. Spleens from IFN-gamma-deficient mice immunized with cardiac myosin showed increased cellularity; greater numbers of CD3+, CD4+, CD8+, and IL-2-producing cells; and heightened ability to produce cytokines on stimulation in vitro. Treatment of mice with recombinant IFN-gamma suppressed the development of myocarditis. CONCLUSIONS: IL-12/IL-12R/STAT4 signaling promotes the development of EAM. In contrast, IFN-gamma plays a protective role. The disease-limiting effects of IFN-gamma might be explained by its ability to control the expansion of activated T lymphocytes.


Subject(s)
Autoimmune Diseases/physiopathology , DNA-Binding Proteins/physiology , Interferon-gamma/physiology , Myocarditis/physiopathology , Receptors, Interleukin/physiology , Trans-Activators/physiology , Animals , Autoimmune Diseases/pathology , Autoimmune Diseases/prevention & control , CD3 Complex/analysis , CD4 Antigens/analysis , CD8 Antigens/analysis , Cells, Cultured , Cytokines/drug effects , Cytokines/metabolism , DNA-Binding Proteins/genetics , Female , Flow Cytometry , Genotype , Interferon-gamma/genetics , Interferon-gamma/pharmacology , Interleukin-12/pharmacology , Mice , Mice, Inbred BALB C , Mice, Knockout , Myocarditis/pathology , Myocarditis/prevention & control , Myocardium/immunology , Myocardium/pathology , Myosins/immunology , Receptors, Interleukin/genetics , Receptors, Interleukin-12 , STAT4 Transcription Factor , Signal Transduction , Spleen/cytology , Spleen/drug effects , Spleen/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Trans-Activators/genetics
2.
Medicine (Baltimore) ; 78(6): 370-81, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10575419

ABSTRACT

We investigated the presence of hypergammaglobulinemia and oligo-/monoclonal gammopathy in 90 patients (from 80 families) with ataxia-telangiectasia ranging in age from 2 to 29 years. Of the 90 patients, 38.8% displayed hypergammaglobulinemia. An isolated increase in IgM was the most common finding (23.3%) followed by a simultaneous increase in IgM and IgG (8.8%), an isolated increase in IgA (3.3%), an elevated level of IgG (2.2%) and a concomitant increase in IgM and IgA (1.1%), respectively. Seven of the patients (8.1%) had oligo-/monoclonal gammopathy. The gammopathies included all major immunoglobulin isotypes. Chemotherapeutic intervention in 2 cases precipitated the emergence of new clones within a matter of weeks. Further investigation of oligo-/monoclonal gammopathies in these patients may lead to a clearer understanding of the clinical course and provide further insight into the underlying mechanisms of B-cell abnormalities in ataxia-telangiectasia.


Subject(s)
Ataxia Telangiectasia/complications , Hypergammaglobulinemia/etiology , Paraproteinemias/etiology , Adolescent , Blood Proteins/analysis , Child , Child, Preschool , Diseases in Twins , Female , Humans , Hypergammaglobulinemia/blood , Immunoglobulin Isotypes/blood , Male , Neoplasms/complications , Paraproteinemias/blood , Paraproteinemias/genetics , Paraproteinemias/pathology , T-Lymphocyte Subsets/pathology
3.
J Immunol ; 162(11): 6401-9, 1999 Jun 01.
Article in English | MEDLINE | ID: mdl-10352253

ABSTRACT

Engagement of TCR by its ligand, the MHC/peptide complex, causes T cell activation. T cells respond positively to stimulation with agonists, and are inhibited by antagonist MHC/peptide ligands. Failure to induce proper conformational changes in the TCR or fast TCR/MHC dissociation are the leading models proposed to explain anergy induction by antagonist ligands. In this study, we demonstrate that presentation of between 1 and 10 complexes of agonist/MHC II by unfixed APC induces T cell anergy that persists up to 7 days and has characteristics similar to anergy induced by antagonist ligand or TCR occupancy without costimulation. Furthermore, anergy-inducing doses of hemagglutinin 306-318 peptide led to the engagement of less than 1000 TCR/CD3 complexes. Thus, engagement of a subthreshold number of TCR by either a low density of agonist/MHC or a 2-3 orders of magnitude higher density of antagonist/MHC causes anergy. Moreover, we show that anergy induced by low agonist concentrations is inhibited in the presence of IL-2 or cyclosporin A, suggesting involvement of the calcineurin signaling pathway.


Subject(s)
Clonal Anergy/immunology , Receptors, Antigen, T-Cell/agonists , Receptors, Antigen, T-Cell/metabolism , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Clonal Anergy/drug effects , Clone Cells , Cyclosporine/pharmacology , Cytokines/biosynthesis , Dose-Response Relationship, Immunologic , Down-Regulation/immunology , HLA-DR1 Antigen/analysis , Hemagglutinin Glycoproteins, Influenza Virus , Hemagglutinins, Viral/analysis , Hemagglutinins, Viral/immunology , Hemagglutinins, Viral/pharmacology , Humans , Immunosuppressive Agents/pharmacology , Interleukin-2/pharmacology , Ligands , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , Macromolecular Substances , Orthomyxoviridae/immunology , Peptide Fragments/analysis , Peptide Fragments/immunology , Peptide Fragments/pharmacology , Receptors, Antigen, T-Cell/antagonists & inhibitors , Receptors, Antigen, T-Cell/biosynthesis , Receptors, Interleukin-2/biosynthesis , T-Lymphocytes/chemistry , Time Factors , Up-Regulation/immunology
4.
J Biol Chem ; 271(13): 7297-300, 1996 Mar 29.
Article in English | MEDLINE | ID: mdl-8631746

ABSTRACT

In contrast to excitable tissues where calcium channels are well characterized, the nature of the B lymphocyte calcium channel is unresolved. Here, we demonstrate by single cell analysis of freshly isolated rat B cells that the anti-immunoglobulin (Ig)-induced calcium influx takes place through a channel which shares pharmacologic and serologic properties with the L-type calcium channel found in excitable tissues. It is sensitive to the dihydropyridines nicardipine and Bay K 8644, to calciseptine, and to an anti-peptide antibody raised against the alpha1 subunit of the L-type calcium channel, but is voltage-insensitive. Anti-alpha1 and anti-alpha2 antibodies stain B but not T lymphocytes. Application of a cGMP agonist, measurement of cGMP levels in anti-Ig-stimulated B cells, and examining the effect of a guanylyl cyclase inhibitor on the anti-Ig response show that cGMP mediates the influx. This possibly involves a cGMP-dependent protein kinase. The anti-Ig-induced response is not abolished by prior treatment of B cells with a high dose of thapsigargin. These findings undermine the widely held belief of a categorical divide between excitable and non-excitable tissue calcium channels, demonstrate the limitations of the capacitative calcium influx theory, and point to a distinction between the calcium response mechanisms utilized by B and T lymphocytes.


Subject(s)
8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Antibodies/pharmacology , B-Lymphocytes/metabolism , Calcium Channel Blockers/pharmacology , Calcium Channels/physiology , Calcium/metabolism , Cyclic GMP/metabolism , 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester/pharmacology , Animals , B-Lymphocytes/cytology , B-Lymphocytes/drug effects , Calcium Channels/drug effects , Calcium Channels/immunology , Calcium Channels, L-Type , Cell Membrane/drug effects , Cell Membrane/metabolism , Cell Separation , Cells, Cultured , Cyclic GMP-Dependent Protein Kinases/metabolism , Egtazic Acid/pharmacology , Elapid Venoms/pharmacology , Immunoglobulin D/pharmacology , Immunoglobulin M/pharmacology , Kinetics , Lymph Nodes/cytology , Lymph Nodes/immunology , Nicardipine/pharmacology , Rats
SELECTION OF CITATIONS
SEARCH DETAIL
...